Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from rand...

por Barash, Steve, Ramirez Campos, Verena, Ning, Xiaoping, Driessen, Maurice T., Krasenbaum, Lynda J., Carr, Karen, Cohen, Joshua M.
Publicado 2021

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate respons...

por Spierings, Egilius L. H., Ning, Xiaoping, Ramirez Campos, Verena, Cohen, Joshua M., Barash, Steve, Buse, Dawn C.
Publicado 2021

Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

por Buse, Dawn C., Gandhi, Sanjay K., Cohen, Joshua M., Ramirez-Campos, Verena, Cloud, Blaine, Yang, Ronghua, Cowan, Robert P.
Publicado 2020

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

por Lipton, Richard B., Cohen, Joshua M., Bibeau, Kristen, Galic, Maja, Seminerio, Michael J., Ramirez Campos, Verena, Halker Singh, Rashmi B., Ailani, Jessica
Publicado 2020

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

por Silberstein, Stephen D., Reshef, Shoshana, Cohen, Joshua M., Gandhi, Sanjay, Seminerio, Michael, Ramirez Campos, Verena, Kessler, Yoel, Thompson, Stephen F., Blumenfeld, Andrew
Publicado 2022